Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies

Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (＞7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Akihiro, Shirai, Izumi, Ogawa, Kyohei, Miura, Akane, Haruhara, Kotaro, Oshiro, Kentaro, Hamaguchi, Akihiko, Yokote, Shinya, Okabe, Masahiro, Ueda, Hiroyuki, Tsuboi, Nobuo, Ikeda, Masato, Yokoo, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841105/
https://www.ncbi.nlm.nih.gov/pubmed/36171121
http://dx.doi.org/10.2169/internalmedicine.0241-22
Descripción
Sumario:Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (＞7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.

Ejemplares similares